# Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

> **NCT07072325** · PHASE1 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Malignant Neoplasm
- Head &Amp; Neck Cancer
- Head and Neck Cancer
- Advanced Head and Neck Carcinoma

## Interventions

- **DRUG:** CD-001

## Key facts

- **NCT ID:** NCT07072325
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07072325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07072325, "Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07072325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*